Compared to adults, newborns are highly susceptible to infections and these infections can cause serious health complications and even death.
Frontline Combo Yields High Remission Rate in Hairy Cell Leukemia
Use of the BRAF inhibitor vemurafenib (Zelboraf) combined with the anti-CD20 monoclonal antibody obinutuzumab (Gazyva) led to high rates of complete remission as frontline therapy